Major Depressive Disorder
Major Depressive Disorder (MDD), also known as clinical or major depression, is a severe mental health condition characterized by at least two weeks of persistent low mood, low self-esteem, and a lack of interest or pleasure in everyday activities, and may involve symptoms such as sadness, angry outbursts, fatigue, feelings of worthlessness, difficulty thinking, and thoughts of suicide. Introduced by US clinicians in the mid-1970s and recognized in the DSM-III by the American Psychiatric Association, MDD is a significant mood disorder impacting daily functioning.
Health Outcomes
- Achieved Remission
- Alleviated D-Tryptophan Levels
- Altered Monoamine Signaling
- Altered Neurobiological Markers
- Changed Functional Connectivity
- Decreased Composite Scores
- Enhanced Neurogenesis in Adults
- Improved Antidepressant Efficacy
- Improved Antidepressant Response
- Improved Antidepressant Support
- Improved Brain-Derived Neurotrophic Factor Level
- Improved Catecholamine Status
- Improved Clinical Effective Rate
- Improved Cognitive Reactivity to Sad Mood
- Improved Depression Severity
- Improved Depression Status
- Improved Depressive Symptoms
- Improved Depressive-Like Behaviours
- Improved Distress of Life Score
- Improved Emotional Behavior
- Improved Emotional Dysregulation
- Improved Emotional Function
- Improved Emotional Functioning
- Improved Emotional Processing
- Improved Emotional State
- Improved Emotional Well-Being Quality of Life
- Improved Emotional Well-being
- Improved Emotional and Behavioral Changes
- Improved Exertion and Emotional Perceptions
- Improved Fatigue Index
- Improved Flexibility or Set Shift
- Improved General Behavioral Scores
- Improved General Psychopathology Subscale
- Improved Global Assessment of Efficacy
- Improved Global Clinical Impression
- Improved Global Clinical Status
- Improved Global Improvement of Symptoms (Clinician-Rated)
- Improved Global Symptom
- Improved Glucocorticoid Negative Feedback on the HPA Axis
- Improved Gut-Brain Axis Related Neurobehavioral Measures
- Improved Gut-Brain Axis-Related Neuropsychiatric Health
- Improved Medication Adherence
- Improved Mental Health
- Improved Mood
- Improved Mood Disturbance
- Improved Neuroendocrine Stress Markers
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Neurotrophic Signaling
- Improved Parental Mood
- Improved Patient Global Impression of Improvement
- Improved Pattern Separation
- Improved Perceived Mental Well-being
- Improved Positive Affect
- Improved Positive Mood States
- Improved Positive Well-Being
- Improved Problem-Solving Skills
- Improved Psychological Distress
- Improved Psychological Status
- Improved Psychological Well-being
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Remission Rate
- Improved Responder Rate
- Improved Response Rate
- Improved Role Emotional
- Improved Self-Rated Vigor
- Improved Serotonin Metabolism
- Improved Set-Shifting Reaction Time
- Improved Significant Response Rate
- Improved Stress-Related Psychiatric Health
- Improved Subjective Recovery
- Improved Subjective Satisfaction
- Improved Synaptic Plasticity
- Improved Therapeutic Efficacy
- Improved Total DASS-42 Score
- Improved Treatment Effective Rate
- Improved Treatment Efficacy
- Improved Vigor-Activity
- Improved Work Productivity
- Increased 3-Hydroxykynurenine to Kynurenine Ratio
- Increased Brain-derived Neurotrophic Factor Level
- Increased Clinical Response Proportion
- Increased DNA Methylation
- Increased GABAergic Signaling
- Increased Insomnia
- Increased Neurogenesis
- Increased P3b Amplitude
- Increased Plasma Serotonin Levels
- Increased Remission Rate
- Increased Serum BDNF Levels
- Increased Systemic GABA Levels
- Increased Time in Bed
- Increased Treatment Effectiveness
- Increased Treatment Response
- Increased Tryptophan Level
- Increased Weight Gain Rate
- Maintained Lower Salivary Cortisol Levels
- Modulated HPA Axis
- No CYP1A2 or CYP3A4 Interaction
- No Change in Plasma GABA Levels
- Normalized HPA Axis Activity
- Reduced 5-Hydroxytryptamine Level
- Reduced Abnormal Brain Plasticity Due to Stress
- Reduced Anhedonia
- Reduced Anthranilic Acid Level
- Reduced Anxiety and Depression (HADS)
- Reduced Appetite Changes
- Reduced Appetite Loss
- Reduced Bifidobacterium and Lactobacillus Counts in Patients with MDD
- Reduced Chocolate Pleasantness Rating
- Reduced Cortical Excitation
- Reduced Crying
- Reduced D-Tryptophan Levels
- Reduced DASS-21 Score
- Reduced Depressed Mood
- Reduced Depression
- Reduced Depression Anxiety Stress Symptoms
- Reduced Depression Rating Score
- Reduced Depression Score
- Reduced Depression Scores at Follow-Up
- Reduced Depression Severity
- Reduced Depression Symptoms
- Reduced Depression and Anxiety Scores
- Reduced Depression-Dejection T-score
- Reduced Depression-like Behavior
- Reduced Depressive Affect
- Reduced Depressive Behavior
- Reduced Depressive Symptom
- Reduced Depressive Symptoms
- Reduced Depressive Thoughts
- Reduced Despair-Like Behavior
- Reduced Emotional Fatigue
- Reduced Fatigue-Inertia
- Reduced General Psychopathology
- Reduced General Psychopathology Score
- Reduced Glabellar Lines
- Reduced Global Symptom Persistence
- Reduced Global Symptoms
- Reduced HADS Global Score
- Reduced Hamilton Depression Rating Scale Score
- Reduced Hippocampal Apoptosis
- Reduced Hyperactivity of the Hypothalamic-Pituitary-Adrenal Axis
- Reduced Incidence of Crying
- Reduced Interference with Daily Life
- Reduced Irritability
- Reduced Kynurenine Level
- Reduced Lethargy and Social Isolation
- Reduced Mental Fatigue
- Reduced Mental Health Symptom
- Reduced Montgomery-Åsberg Depression Rating Scale Score
- Reduced Mood Disturbance
- Reduced N-acetylaspartate Level
- Reduced Negative Emotional Responses
- Reduced Negative Mood States
- Reduced Neuropeptide Y Level
- Reduced P3b Amplitude
- Reduced Patient Assessment Score
- Reduced Perceived Stress
- Reduced Prefrontal Cortex Activation
- Reduced Prospective Consumption
- Reduced Psychiatric Problems
- Reduced Psychiatric Symptom Severity
- Reduced Psychological Distress
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Psychosocial Symptom
- Reduced Relapse
- Reduced Relapse Rate
- Reduced Relative Abundance of Coprococcus Genus
- Reduced Risk of Crying
- Reduced Seasonal Affective Disorder Symptom
- Reduced Serum Kynurenine Levels
- Reduced Sleep Duration
- Reduced Stress-Induced Reduction in Diurnal Temperature Amplitude
- Reduced Suicide Attempt
- Reduced Suicide Ideation
- Reduced Suicide-Related Emergency or Hospital Visit
- Reduced Suicide-Related Endpoints
- Reduced Symptoms
- Reduced Time to Antidepressant Onset
- Reduced Total Mood Disturbance
- Reduced Total Score on Depression Anxiety Stress Scales (DASS-42)
- Reduced VIA Positivity
- Reduced Washing Solution Volume
- Stable Brain Metabolite Levels
- Worsened Depression Score